PWE-040 Antithrombotic medications in upper gi bleeding: frequency of use, timing of re-prescription & outcomes

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

Upper gastrointestinal bleeding (UGIB) is a common medical emergency1. The use of antithrombotic (AT) medications (antiplatelets or anticoagulants/DOACs) is increasing. These drugs significantly increase the risk of UGIB2. Our aim was to assess the use of AT medications and NSAIDs on outcome after UGIB and the timing of re-prescription of these drugs.

Method

A six month audit (01.04.16–30.09.16) of patients undergoing endoscopy for UGIB was conducted. Demographics, drug use and Full Rockall risk score (FRS) were calculated. Outcomes included transfusion, endoscopic therapy, re-bleeding <7 days and 30 day mortality. We assessed prescription of ATs and NSAIDs following presentation.

Results

206 patients were identified. 48% were taking AT drugs or NSAIDs. Patients taking ATs were older (69 vs 53 years; p<0.001) and had higher FRS (+32.0%, p<0.001) than those not. Peptic ulcers were more common (38% vs 22%; p=0.02) and varices less common (4% vs 15%; p<0.02) in patients on ATs vs those not. Need for transfusion (29% vs 27%) and need for endoscopic therapy (45% vs 55%) were similar in both groups.

Results

Aspirin and ADP-inhibitors were restarted <3 days in 63% and 65% respectively. 71.4% and 50% respectively had these drug restarted <7 days, and 17% and 13% respectively had them permanently discontinued. NSAIDs were permanently discontinued in 91%. All 6 patients on DOACs had the drug restarted <3 days. Comparing those on ATs vs those not on ATs there was no difference in rebleeding (4.11% vs 6.67%; p=0.501) or mortality (10.9% vs 7.07%; p=0.447).

Conclusion

Use of AT drugs is common in patients presenting with UGIB. Most patients are restarted on these medications<3 days of their bleed. Despite patients on ATs being older and with higher FRS, outcomes after UGIB, including rebleeding and survival, are similar for patients taking or not taking AT medications.

Disclosure of Interest

None Declared

Related Topics

    loading  Loading Related Articles